Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy
Lund University, Sweden.
Lund University, Sweden.
Imperial College, UK.
Lund University, Sweden.
Show others and affiliations
2021 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 11, article id 4201Article in journal (Refereed) Published
Abstract [en]

Alternative ways to prevent and treat infectious diseases are needed. Previously, we identified a fungal peptide, NZX, that was comparable to rifampicin in lowering M. tuberculosis load in a murine tuberculosis (TB) infection model. Here we assessed the potential synergy between this cationic host defence peptide (CHDP) and the current TB drugs and analysed its pharmacokinetics. We found additive effect of this peptide with isoniazid and ethambutol and confirmed these results with ethambutol in a murine TB-model. In vivo, the peptide remained stable in circulation and preserved lung structure better than ethambutol alone. Antibiotic resistance studies did not induce mutants with reduced susceptibility to the peptide. We further observed that this peptide was effective against nontuberculous mycobacteria (NTM), such as M. avium and M. abscessus, and several Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. In conclusion, the presented data supports a role for this CHDP in the treatment of drug resistant organisms.

Place, publisher, year, edition, pages
2021. Vol. 11, article id 4201
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:ri:diva-52583DOI: 10.1038/s41598-021-83755-3Scopus ID: 2-s2.0-85101252476OAI: oai:DiVA.org:ri-52583DiVA, id: diva2:1536782
Note

Open access funding provided by Lund University. NK, IGM and BR thank the UK Medical Research Council for support in the MRC Centre for Molecular Bacteriology and Infection, Imperial College London. The research was funded by the Swedish Heart–Lung Foundation (20200378), Alfred Österlunds Foundation, Royal Physiographic Society of Lund, Swedish Research Council and European Union’s Seventh Framework Programme (FP7/2007–2013) under grant agreement no 604182, FORMAMP-Innovative Nanoformulation of Antimicrobial Peptides to Treat Bacterial Infectious Diseases

Available from: 2021-03-12 Created: 2021-03-12 Last updated: 2023-05-09Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records

Millqvist-Fureby, Anna

Search in DiVA

By author/editor
Millqvist-Fureby, Anna
By organisation
Manufacturing ProcessesChemistry, Biomaterials and TextilesChemical Process and Pharmaceutical Development
In the same journal
Scientific Reports
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf